4 Healthcare Stock Stories for a Thursday Cure

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Pfizer (NYSE:PFE): Closing price $26.83

Pfizer’s partner GlycoMimetics has concluded the enrollment of patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate. This randomized, double-blinded evaluation examined the efficacy, safety and pharmacokinetics of GMI-1070 in hospitalized sickle cell disease patients experiencing vaso-occlusive crisis. GlycoMimetics has enrolled 76 patients from the  ages of 12 through 65 at 22 trial sites in the United States and Canada. The company expects topline data in the second quarter.

pfe

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business